Endothelin Receptor B Antagonists Reduce Glioma Cell Viability
Author Information
Author(s): Jennifer P. Montgomery, Paul H. Patterson
Primary Institution: California Institute of Technology
Hypothesis
Do endothelin receptor B antagonists affect glioma cell viability independently of their receptor?
Conclusion
ETRB antagonists reduce glioma cell viability in vitro through mechanisms not involving ETRB inhibition.
Supporting Evidence
- A-192621 and BQ788 significantly reduce viable cell numbers in glioma and melanoma cell lines.
- A-192621 induces G2/M cell cycle arrest and apoptosis in glioma cells.
- Microarray analysis shows up-regulation of DNA damage-inducible genes following A-192621 treatment.
Takeaway
This study shows that certain drugs can make brain cancer cells die without using the usual pathways we thought they would.
Methodology
Glioma and melanoma cell lines were treated with ETRB antagonists, and cell viability was assessed using fluorescence-based assays and gene expression analyzed via microarray.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo conditions.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website